Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision		 Previous revision
ophthalmologic_monitoring_management_raf_mek_pathway_inhibitors [2026/07/01 22:34] – Scott Larsonophthalmologic_monitoring_management_raf_mek_pathway_inhibitors [2026/07/01 22:38] (current) – [Ophthalmologic Monitoring and Management for RAF/MEK Pathway Inhibitors] Scott Larson
Line 1: Line 1:
 ====== Ophthalmologic Monitoring and Management for RAF/MEK Pathway Inhibitors ====== ====== Ophthalmologic Monitoring and Management for RAF/MEK Pathway Inhibitors ======
  
-Here is a comprehensive overview of recommended ophthalmologic monitoring protocols and management strategies for patients on RAF/MEK pathway inhibitors, applicable to tovorafenib and its drug class.+Here is a comprehensive overview of recommended ophthalmologic monitoring protocols and management strategies for patients on [[mapk_pathway_drugs_ocular_toxicity|RAF/MEK pathway inhibitors]], applicable to tovorafenib and its drug class.
  
 ===== Baseline Ophthalmologic Assessment ===== ===== Baseline Ophthalmologic Assessment =====
Line 51: Line 51:
  
 ^ Ocular Toxicity ^ Management ^ References ^ ^ Ocular Toxicity ^ Management ^ References ^
- 
 | RPED (any grade) | Withhold for up to 3 weeks; if improved, resume at same or lower dose; if not improved, discontinue or reduce dose | Jeng-Miller et al. 2024; Trametinib FDA label | | RPED (any grade) | Withhold for up to 3 weeks; if improved, resume at same or lower dose; if not improved, discontinue or reduce dose | Jeng-Miller et al. 2024; Trametinib FDA label |
- 
 | Retinal vein occlusion | Permanently discontinue | Trametinib FDA label | | Retinal vein occlusion | Permanently discontinue | Trametinib FDA label |
- 
 | Serous retinopathy (mild, asymptomatic) | May continue treatment with close monitoring; dose modification at physician discretion | Francis et al. 2017; Weber et al. 2016 | | Serous retinopathy (mild, asymptomatic) | May continue treatment with close monitoring; dose modification at physician discretion | Francis et al. 2017; Weber et al. 2016 |
- 
 | Serous retinopathy (symptomatic, Grade ≥2) | Withhold; resume at lower dose upon resolution | Weber et al. 2016 | | Serous retinopathy (symptomatic, Grade ≥2) | Withhold; resume at lower dose upon resolution | Weber et al. 2016 |
- 
 | Uveitis (BRAF inhibitor-related) | Dose reduction; topical steroids; discontinue if refractory | Urner-Bloch et al. 2014; Mettler et al. 2021 | | Uveitis (BRAF inhibitor-related) | Dose reduction; topical steroids; discontinue if refractory | Urner-Bloch et al. 2014; Mettler et al. 2021 |
  
Line 83: Line 78:
   - Méndez-Martínez S, Calvo P, Ruiz-Moreno O, et al. Ocular Adverse Events Associated With MEK Inhibitors. //Retina//. 2019;39(8):1435-1450. [[https://doi.org/10.1097/IAE.0000000000002451|DOI]]   - Méndez-Martínez S, Calvo P, Ruiz-Moreno O, et al. Ocular Adverse Events Associated With MEK Inhibitors. //Retina//. 2019;39(8):1435-1450. [[https://doi.org/10.1097/IAE.0000000000002451|DOI]]
   - Urner-Bloch U, Urner M, Jaberg-Bentele N, et al. MEK Inhibitor-Associated Retinopathy (MEKAR) in Metastatic Melanoma: Long-Term Ophthalmic Effects. //Eur J Cancer//. 2016;65:130-8. [[https://doi.org/10.1016/j.ejca.2016.06.018|DOI]]   - Urner-Bloch U, Urner M, Jaberg-Bentele N, et al. MEK Inhibitor-Associated Retinopathy (MEKAR) in Metastatic Melanoma: Long-Term Ophthalmic Effects. //Eur J Cancer//. 2016;65:130-8. [[https://doi.org/10.1016/j.ejca.2016.06.018|DOI]]
 +
 +{{tag>drugs}}